Cite
HARVARD Citation
Rovati, L. et al. (2020). Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. Osteoarthritis and cartilage. 28 (1), pp. 22-30. [Online].